Please login to the form below

Not currently logged in
Email:
Password:

Andrew Witty

This page shows the latest Andrew Witty news and features for those working in and with pharma, biotech and healthcare.

GlaxoSmithKline reportedly looking to sell select antibiotic brands

GlaxoSmithKline reportedly looking to sell select antibiotic brands

GSK gained the two vaccines as part of a $20bn asset swap with Novartis in 2015, which was orchestrated by previous GSK CEO Sir Andrew Witty.

Latest news

More from news
Approximately 6 fully matching, plus 124 partially matching documents found.

Latest Intelligence

  • Pharma deals in July 2015 Pharma deals in July 2015

    Andrew Witty some weeks ago commented that the low cost of capital is causing companies to pay prices based on 'stretched valuations'.

  • Pharma deals during July 2014 Pharma deals during July 2014

    Elsewhere, London's Financial Times reported that GSK's CEO Andrew Witty had suggested in an interview that the new consumer healthcare business being set up as a JV with Novartis

  • Pharma deals during April 2014 Pharma deals during April 2014

    This is the “hot field” in the industry and of course Novartis, a cancer heavyweight is ideally placed to maximise the potential of GSK's, by Andrew Witty's own admission,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Former GSK CEO joins Synthego’s advisory board Former GSK CEO joins Synthego’s advisory board

    Sir Andrew Witty will expand the team’s bioinformatics expertise. Genome engineering solutions provider Synthego has appointed Sir Andrew Witty to its advisory board, a role that will see him work ... Andrew’s appointment strengthens the company’s

  • Former RBS head takes the reins as GSK chair Former RBS head takes the reins as GSK chair

    This week Sir Philip backed GSK's under fire CEO Sir Andrew Witty, who has weathered a tough two years of scandals and continually falling sales. ... There are always shareholders who have points to make, but I certainly hope Andrew is here for a good

  • Ex Sanofi boss joins Boston start-up Ex Sanofi boss joins Boston start-up

    He was one of several senior management staffers in-line to take GSK's top job, but ultimately lost out to Sir Andrew Witty in 2008, prompting his move to the

  • Sanofi CEO Viehbacher to head EFPIA Sanofi CEO Viehbacher to head EFPIA

    He was elected to the position in November 2012 to replace GlaxoSmithKline's Andrew Witty, and will remain as president for two years during which time he will lead the pharma

  • Sanofi's Christopher Viehbacher to take the reins at EFPIA Sanofi's Christopher Viehbacher to take the reins at EFPIA

    He will take over the leadership of the European pharma trade body from GlaxoSmithKline's Andrew Witty in June 2013, when he will serve a two-year term.

More from appointments
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics